PUSHING THE BOUNDARIES
At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness
We are bringing new science to the design and development of next generation retina medicines, starting with our ABC Platform
1 Molecule, 1 Target
tarcocimab tedromer (KSI-301): inhibits VEGF for retinal vascular diseases
1 Molecule, 2 Targets
KSI-501: dual inhibition of IL-6 (anti-IL-6 antibody) and VEGF (VEGF-Trap) for patients that historically do not respond well to anti-VEGF alone
1 Molecule, 3 Targets
KSI-601: for multifactorial diseases, such as dry AMD and glaucoma
PRECISION ENGINEERED FOR INCREASED DURABILITY AND EFFICACY
Designed for the retina, the ABC platform uses our bio-inspired polymer to orchestrate water around a purpose-built antibody to power new and enduring capabilities in retina care
1 or 2 Targets
Optically clear, branched, high-molecular weight phosphorylcholine polymer.
It binds to water to create a water force-field around the antibody. This shields it from non-specific interactions and allows it to focus on its target.
Stable, Single-Site Specific Linkage
Stable, site-specific linkage that is non-degradative and non-erodible. The bioconjugate enters and exits the eye intact leaving no residual material.
Engineered to bind to its target with high specificity and to be immune silent. Designed for 1 or 2 targets.
Revolutionizing treatment of multifactorial retinal diseases with triplet medicines
Our triplet medicines combine the benefits of our ABC Platform with the sustained release of 100’s of small molecules to impact three mechanisms of disease enabling treatment of complex disorders such as dry AMD.
Conjugated to phosphorylcholine biopolymer designed for improved durability, excellent retinal bioavailability, and rapid systemic clearance.
New, single molecule
Designed for retinal diseases to modulate multiple intracellular and extracellular disease pathways.
Embedded and attached into the phosphorylcholine biopolymer and designed for high biocompatibility, high drug loading, and sustained release.
BUILT TO DIFFERENTIATE AND ENDURE
The ABC Platform has a high molecular weight and formulation strength. This can provide an important dosing advantage
Equivalent values are shown as fold changes relative to aflibercept. kDa= kilodalton.
†Lower affinity of bevacizumab precludes a useful comparison.
‡Assumes 2x starting molar dose and similar ocular T1/2 as aflibercept
TARCOCIMAB TEDROMER (KSI-301): GENERATION 2.0 ANTI-VEGF RETINAL MEDICINE
Same Where It Matters
- Clinically proven targets
- Antibody-based biologic
- Intravitreal: safest method of administration
- Optically clear, no residues
- Fast and potent clinical responses
Different Where It Counts
- Designed-in ocular durability
- Designed-in rapid systemic clearance
- Improved bioavailability
- Improved biocompatibility
- Improved stability
MORE THAN THE SUM OF ITS PARTS
The ABC Platform structures water at critical binding interfaces to make medicines last longer in the eye and improve their therapeutic benefit
Remarkable Intraocular Half-life
Medicines built on the ABC Platform (e.g., KSI-301) last longer and better maintain therapeutic concentration levels in the eye
Excellent Retinal Bioavailability
The ABC Platform improves therapeutic absorption and distribution in the eye
Deeper Inhibitory Potency
The ABC Platform binds and inhibits VEGF in a more relevant way
Fast Systemic Clearing
The ABC Platform is designed to clear the body quickly after it exits from the eye
TAKE A 3-DIMENSIONAL TOUR
Tour our Antibody Biopolymer Conjugate (ABC) PlatformTM in 360° below.
Click and drag to see different views. Scroll or pinch to zoom.
Please be patient while the 3-D model loads